Scientists at Beth Israel Deaconess Medical Center who had been researching adenovirus vector vaccines for the past two decades quickly shifted their focus to SARS-CoV-2 last year, resulting in a stable, single-dose shot based on adenovirus 26 that is now Johnson & Johnson's COVID-19 vaccine. An HIV vaccine based on the same technology is in Phase 3 testing, and vaccines for Zika and Ebola viruses could follow.
Decades of research paved way for COVID-19 vaccines
Sign up for FBR SmartBrief
Biomedical Research News
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.